TY - JOUR
T1 - An abundant perivascular source of stem cells for bone tissue engineering
AU - James, Aaron W.
AU - Zara, Janette N.
AU - Corselli, Mirko
AU - Askarinam, Asal
AU - Zhou, Ann M.
AU - Hourfar, Alireza
AU - Nguyen, Alan
AU - Megerdichian, Silva
AU - Asatrian, Greg
AU - Pang, Shen
AU - Stoker, David
AU - Zhang, Xinli
AU - Wu, Benjamin
AU - Ting, Kang
AU - Péault, Bruno
AU - Soo, Chia
PY - 2012
Y1 - 2012
N2 - Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is dispensable and accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which has disadvantages for tissue regeneration. In the present study, we prospectively purified human perivascular stem cells (PSCs) from n=60 samples of human lipoaspirate and documented their frequency, viability, and variation with patient demographics. PSCs are a fluorescence-activated cell sorting-sorted population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells (CD45-, CD146-, CD34+), each of which we have previously reported to have properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These numbers were minimally changed by age, gender, or body mass index of the patient or by length of refrigerated storage time between liposuction and processing. In a previous publication, we observed that human PSCs (hPSCs) formed significantly more bone in vivo in comparison with unsorted human SVF (hSVF) in an intramuscular implantation model. We now extend this finding to a bone injury model, observing that purified hPSCs led to significantly greater healing of mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). These studies suggest that adipose-derived hPSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy.
AB - Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is dispensable and accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which has disadvantages for tissue regeneration. In the present study, we prospectively purified human perivascular stem cells (PSCs) from n=60 samples of human lipoaspirate and documented their frequency, viability, and variation with patient demographics. PSCs are a fluorescence-activated cell sorting-sorted population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells (CD45-, CD146-, CD34+), each of which we have previously reported to have properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These numbers were minimally changed by age, gender, or body mass index of the patient or by length of refrigerated storage time between liposuction and processing. In a previous publication, we observed that human PSCs (hPSCs) formed significantly more bone in vivo in comparison with unsorted human SVF (hSVF) in an intramuscular implantation model. We now extend this finding to a bone injury model, observing that purified hPSCs led to significantly greater healing of mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). These studies suggest that adipose-derived hPSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy.
KW - Adult stem cells
KW - Cell biology
KW - Cell surface markers
KW - Cell transplantation
KW - Cellular therapy
KW - Mesenchymal stem cells
KW - Osteoblast
UR - http://www.scopus.com/inward/record.url?scp=84873030200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873030200&partnerID=8YFLogxK
U2 - 10.5966/sctm.2012-0053
DO - 10.5966/sctm.2012-0053
M3 - Article
C2 - 23197874
AN - SCOPUS:84873030200
SN - 2157-6564
VL - 1
SP - 673
EP - 684
JO - Stem Cells Translational Medicine
JF - Stem Cells Translational Medicine
IS - 9
ER -